首頁 > 市場調查報告書 > 醫療設備

市場調查報告書

商品編碼

1410015

妊娠毒血症診斷市場：2023 年至 2028 年預測

Preeclampsia Diagnostics Market - Forecasts from 2023 to 2028

出版日期: 2023年12月11日 | 出版商:

Knowledge Sourcing Intelligence | 英文 148 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

全球妊娠毒血症診斷市場預計在預測期內將以 10.87% 的複合年成長率成長。

妊娠毒血症是一種高血壓問題，由於尿液中蛋白質含量高（表示腎臟受損），會導致孕婦出現併發症。全球孕婦妊娠毒血症盛行率不斷上升，增加了對診斷測試的需求，從而啟動了妊娠毒血症診斷市場。此外，人們對併發症引起的風險因素的認知不斷提高，加上政府採取的措施和增強預測的技術進步，預計將在預測期內進一步推動妊娠毒血症診斷市場的發展。

妊娠毒血症患者數量不斷增加

由於血壓調節不規律，全球妊娠毒血症患者數量不斷增加，這是妊娠毒血症診斷市場的關鍵成長動力。根據美國國立衛生研究院的數據，妊娠毒血症併發症每年導致全球約 5 萬名孕產婦死亡和約 50 萬名胎兒死亡。此外，疾病預防控制中心估計，在美國20 至 44 歲的女性中，每年每 12 至 17 次懷孕中就有 1 人患有高血壓。高血壓現在在懷孕期間很常見，這是妊娠毒血症的一個跡象。即使在懷孕後，妊娠毒血症也會為女性帶來問題，這表明需要預防和妊娠毒血症診斷測試。

母親和嬰兒的多種危險因素

由於妊娠毒血症對母親和胎兒都有各種副作用，因此需要妊娠毒血症的治療，並且正在推動妊娠毒血症診斷市場的發展。妊娠毒血症會導致早產、呼吸和餵食問題，在極少數情況下還會損害母親和嬰兒的健康。嬰兒可能患有子宮內生長受限 (IUGR)，各種研究表明出生時患有 IUGR 的兒童成年後更容易患糖尿病、鬱血性心臟衰竭和高血壓。根據妊娠毒血症基金會的數據，每年出生的 3,000 萬名嬰兒中約有 15% 患有妊娠毒血症。

政府和其他機構的意識計劃

旨在提高對妊娠毒血症併發症認知的政府計劃正在推動妊娠毒血症診斷市場的發展。加州公共衛生部正在進行一項宣傳宣傳活動，將五月定為妊娠毒血症症意識月。此外，該國的孕產婦、兒童和青少年健康（MCAH）部門以多種語言提供有關妊娠毒血症的體徵和症狀的資訊，包括阿拉伯語、中文、英語、波斯語、韓語、西班牙語-他加祿語和越南語。存在以提高認知。此外，各種組織的宣傳活動也預計將推動妊娠毒血症診斷市場的發展。

技術進步與創新

醫療保健產業的技術進步正在提高妊娠毒血症檢測的準確性並推動妊娠毒血症診斷市場的發展。 2023 年 3 月，北威爾斯引入了一項創新的面對面胎盤生長因子測試，以減少死產和早產。該測試只需 15 分鐘即可測量 PLGF 水平，並允許孕婦根據風險快速進行分類。此外，Ascertain 和 Caire Health（Northwell Health 和 Aegis Ventures 的合資企業）宣布了一種新演算法來預測妊娠毒血症並解決日益惡化的死亡率問題。 Ascertain 的演算法比目前的預測標準提高了 10-15%。該公司的創投也表示，妊娠毒血症是可以透過機器學習來治療的。

市場機會

孕婦高血壓盛行率的增加為擴大妊娠毒血症診斷市場提供了機會。此外，醫療保健產業的投資前景為進入妊娠毒血症診斷市場提供了巨大的機會。例如，Mirvie 在 B 輪融資中籌集了 6,000 萬美元，用於開發妊娠毒血症檢測的創新設備。子癲前症基金會的 Vision Grant 計畫每年提供高達 25,000 美元的資金，用於妊娠毒血症、HELLP 症候群和相關妊娠高血壓症候群的研究。此外，透過各種宣傳計劃提高孕婦的認知以及提高診斷測試的可及性也有望推動妊娠毒血症診斷市場的發展，並為市場擴張提供機會。

北美預計將成為主導市場

預計在預測期內，北美地區將在全球妊娠毒血症診斷市場中佔據重要佔有率。造成這一比例的因素包括該地區妊娠毒血症併發症的增加以及女性採用妊娠毒血症診斷測試的意識提高。例如，根據妊娠毒血症基金會的數據，過去 20 年來，美國妊娠毒血症的盛行率增加了 25%。此外，最近的技術開拓以及 Quidel Corporation 和 Prestige Brands Holdings 等市場領導的存在進一步增強了該地區妊娠毒血症診斷市場的潛力。

妊娠毒血症診斷市場參與者

Atlas Medical成立於1996年，提供高品質的診斷劑和套件。該公司提供用於檢測甲狀腺和不孕症領域關鍵激素的 HCG 乳膠套件，以及用於孕婦的獨立袋裝 HCG 檢測盒。 EKF Diagnostics Holdings 專注於即時檢測、中心實驗室檢測、酵素製造和契約製造。該公司提供血紅蛋白分析儀來識別患有妊娠期糖尿病的女性並控制病情。

主要市場開拓

2022 年 5 月，Metabolomics Diagnostics 將與子癇前症基金會合作，透過創建準確且偏差較小的測試來改善妊娠毒血症的預測。此外，此夥伴關係旨在透過教育和預防不良後果來改善孕產婦健康。 2021年6月，Lifecell在印度啟動了早發性和晚發性妊娠毒血症篩檢。該公司已成為印度第一家提供早發和晚發篩檢的提供者。篩檢小組現在包括額外的 Sflt-1 生物標記物，即使在懷孕晚期也有助於準確診斷。

Preeclampsia is a hypertensive problem that creates complex problems in pregnant women by high levels of protein in urine indicating kidney damage. The growing prevalence of preeclampsia in pregnant women globally is creating a demand for diagnostic tests thereby boosting the preeclampsia diagnostics market. Moreover, the rising awareness about the risk factors from the complication coupled with government initiatives and technological advancements for enhanced prediction is further contemplated to boost the preeclampsia diagnostics market throughout the forecast period.

Growing Prevalence of Preeclampsia Cases

The rising number of global preeclampsia cases due to irregular regulation of blood pressure is a major growth driver of the preeclampsia diagnostics market. According to National Institute of Health, around 50,000 maternal deaths and 500,000 fetal deaths occur each year worldwide due to preeclampsia complications. Moreover, hypertension occurs in 1 in every 12 - 17 pregnancies each year for women aged 20-44 years in the US as per the CDC estimates. High blood pressure is very common nowadays in pregnancy which is a defining feature of preeclampsia. Preeclampsia may create problems for women even after pregnancy showing the need for prevention and need for preeclampsia diagnostics tests thereby it is expected to drive the preeclampsia diagnostics market.

Multiple Risk Factors for Mother and Baby

There are various side effects of preeclampsia both on mother and baby and thus, it is required to treat the preeclampsia thereby it propels the preeclampsia diagnostics market. It may cause preterm births which increase breathing and feeding problems and in rare cases, it may result in maternal and infant health. Babies may suffer from Intrauterine Growth Restriction (IUGR) and various studies have shown that children born with IUGR are more prone to diabetes, congestive heart failure, and hypertension in their adult age. According to the Preeclampsia Foundation, around 15% of 30 million infants born each year are associated with preeclampsia.

Government and Other Institutions' Awareness Program

The government programs to raise awareness about preeclampsia complications are driving the preeclampsia diagnostics market. The California Department of Public Health runs a communication campaign in May as a preeclampsia awareness month. Moreover, the Maternal, Child, and Adolescent Health (MCAH) division of the country created a social media presence to increase awareness about signs and symptoms of preeclampsia in several languages including Arabic, Chinese, English, Farsi, Korean, Spanish Tagalog, and Vietnamese. Additionally, the campaigns by various organizations are also expected to boost the preeclampsia diagnostics market. For instance, the Check Know Share campaign was launched by Preeclampsia Foundation in May 2020 to urge pregnant women to check their blood pressure, know and understand their numbers and share with their healthcare provider. This was also the theme of the preeclampsia awareness month of 2020.

Technological Advancements and Innovation

The technological advancements in the healthcare industry, enhancing the precision of preeclampsia test is boosting the preeclampsia diagnostics market. In March 2023, an innovative in-person placental growth factor test was introduced in North Wales which reduces stillbirths and pre-term deliveries. This test measures PLGF levels in just 15 minutes and enables quickly segmenting pregnant women by risk. Moreover, a new algorithm for predicting preeclampsia and tackling worsening mortality rates was announced by Ascertain and Caire Health (Joint Venture by Northwell Health and Aegis Ventures). Ascertain's algorithm showed a 10-15% increase over current predictive standards. The company's VC also said that preeclampsia is extremely addressable with machine learning.

Opportunities in the Market

The growing prevalence of hypertension in pregnant women provides a good opportunity for preeclampsia diagnostics market expansion. Moreover, investment prospects in the healthcare industry provide a major opportunity to enter the preeclampsia diagnostics market. For instance, Mirvie raised $60 million in series B funding for the development of breakthrough devices for preeclampsia tests. The Vision Grant Program by Preeclampsia Foundation provides financial help of up to $25,000 every year to study preeclampsia, HELLP syndrome, and related hypertensive disorders of pregnancy. Further, the rising awareness among pregnant women due to various awareness programs and increased accessibility to diagnostic tests is also anticipated to propel the preeclampsia diagnostics market thereby providing an excellent opportunity for market expansion.

North America is an Expected Dominant Market

The North American region is expected to hold a significant share of the global preeclampsia diagnostics market during the forecasted period. Various factors attributed to such a share are rising preeclampsia complications in the region and rising awareness among women to adopt the preeclampsia diagnostics test. For instance, the prevalence rate of preeclampsia has increased by 25% in the last two decades in America as per the Preeclampsia Foundation. Moreover, the recent technological developments and presence of market leaders such as Quidel Corporation and Prestige Brands Holdings further enhance the scope of the preeclampsia diagnostics market in the region.

Preeclampsia Diagnostics Market Players

Atlas Medical, founded in 1996 is a supplier of quality diagnostic reagents and kits. The company provides HCG latex kits to detect major hormones in the fields of thyroid and fertility, and HCG test cassettes, individually pouched for pregnant women.
EKF Diagnostics Holdings PLC focuses on point-of-care testing, central laboratory tests, enzyme manufacturing, and the provision of contract manufacturing. The company offers a range of hemoglobin analyzers to identify women with gestational diabetes and helps in managing their condition.

Key Market Development

In May 2022, Metabolomics Diagnostics entered into a partnership with Preeclampsia Foundation to improvise preeclampsia prediction by creating precise and less biased tests. Moreover, the partnership aims to improve maternal health by educating and preventing bad outcomes.
In June 2021, LifeCell launched screening for both early-onset and late-onset preeclampsia screening in India. The company became the first provider in India to offer screening for the early and late-onset. There is an addition of the Sflt-1 biomarker in the screening panel to help in accurate diagnosis even in the third trimester.

Segmentation:

By Test Type

Blood Test
Urine Test
Others

By Products & Services

Instruments
Reagents & Consumables
Services

By End-User

Hospitals
Diagnostic Centers
Others

By Geography

North America
United States
Canada
Mexico
South America
Brazil
Argentina
Others
Europe
United Kingdom
Germany
France
Spain
Others
Middle East and Africa
Saudi Arabia
UAE
Israel
Others
Asia Pacific
Japan
China
India
South Korea
Indonesia
Thailand
Others

1. INTRODUCTION

1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Market Segmentation
1.5. Currency
1.6. Assumptions
1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

2.1. Research Data
2.2. Assumptions

3. EXECUTIVE SUMMARY

3.1. Research Highlights

4. MARKET DYNAMICS

4.1. Market Drivers
4.2. Market Restraints
4.3. Porter's Five Force Analysis
- 4.3.1. Bargaining Power of Suppliers
- 4.3.2. Bargaining Power of Buyers
- 4.3.3. Threat of New Entrants
- 4.3.4. Threat of Substitutes
- 4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis

5. PREECLAMPSIA DIAGNOSTICS MARKET, BY TEST TYPE

5.1. Introduction
5.2. Blood Test
5.3. Urine Test
5.4. Others

6. PREECLAMPSIA DIAGNOSTICS MARKET, BY PRODUCTS & SERVICES

6.1. Introduction
6.2. Instruments
6.3. Reagents & Consumables
6.4. Services

7. PREECLAMPSIA DIAGNOSTICS MARKET, BY END-USER

7.1. Introduction
7.2. Hospitals
7.3. Diagnostic Centers
7.4. Others

8. PREECLAMPSIA DIAGNOSTICS MARKET, BY GEOGRAPHY

8.1. Introduction
8.2. North America
- 8.2.1. United States
- 8.2.2. Canada
- 8.2.3. Mexico
8.3. South America
- 8.3.1. Brazil
- 8.3.2. Argentina
- 8.3.3. Others
8.4. Europe
- 8.4.1. United Kingdom
- 8.4.2. Germany
- 8.4.3. France
- 8.4.4. Spain
- 8.4.5. Others
8.5. The Middle East and Africa
- 8.5.1. Saudi Arabia
- 8.5.2. UAE
- 8.5.3. Israel
- 8.5.4. Others
8.6. Asia Pacific
- 8.6.1. Japan
- 8.6.2. China
- 8.6.3. India
- 8.6.4. South Korea
- 8.6.5. Indonesia
- 8.6.6. Thailand
- 8.6.7. Others